FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	PPROVAL							
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b)

1. Name and Address of Reporting Person* Broadfoot Jill Marie (Last) (First) (Middle) 3545 JOHN HOPKINS COURT, SUITE 250					<u>aT</u>	2. Issuer Name and Ticker or Trading Symbol aTYR PHARMA INC [LIFE] 3. Date of Earliest Transaction (Month/Day/Year) 05/24/2022								(Che	Relationship of Reporting Person(s) to Issuer heck all applicable) Director 10% Owner X Officer (give title below) below) Chief Financial Officer				
(Street) SAN DII			92121 (Zip)		4. li	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Inc Line)	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Trans: Date (Month/L					2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 3) 8) 4. Securities Acquired (ADisposed Of (D) (Instr. 3) 5)					es Form ally (D) of following (I) (II		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
						Code	v	Amount	(A) or Pi		rice	Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Common Stock													12,290(1)			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Date, T	1. Fransa Code (I 3)		ı of i		6. Date Exercisal Expiration Date (Month/Day/Year)		of Secur r) Underly Derivati		itle and Amount lecurities derlying ivative Security tr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
			Code V (A) (D) Date Exercisa				Date Exercisab		xpiration ate	Title	or Nur of	nount Imber ares							
Employee Stock Option (right to buy)	\$2.81	05/24/2022			A		75,347		(2)	0	5/24/2032	Common Stock	75,	347	\$0.00	75,347	7	D	

Explanation of Responses:

- 1. Includes 178 shares acquired under the Company's 2015 Employee Stock Purchase Plan (ESPP) on May 13, 2022.
- 2. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 24, 2022, such that this option will be fully exercisable on May 24, 2026. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.

Remarks:

Nancy E. Denyes, attorney-in-

** Signature of Reporting Person

fact

05/26/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.